Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluocortolone→

Fluocortolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
152-97-6
Molecular formula
C22H29FO4
Molecular weight
376.5 g/mol
Drug class
Synthetic glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates glucocorticoid receptors and suppresses inflammatory gene expression, cytokine production and immune-cell migration, reducing erythema, oedema and pruritus.
Indications / reported uses
  • Topical treatment of corticosteroid-responsive inflammatory dermatoses with dermatological formulations
  • Rectal formulations of fluocortolone combinations are used for symptomatic treatment of haemorrhoidal inflammation and proctitis where authorised; formulations and indications are route-specific

Sources: UK product information — Fluocortolone-containing products · NLM MeSH — Fluocortolone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluocortolone Environmental Risk Assessment (ERA) (the Fluocortolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.